High Throughput Genomics, a Tucson, Ariz.-based array shop that to date has specialized in selling its plate-based nuclease protection technology to pharmaceutical companies, has decided to begin offering content, according to a company official.
HTG CEO Bill Radany told BioArray News last week that the firm is planning a series of fixed arrays “targeting genes of large interest,” including cytokines and genes related to apoptosis and cell cycle, that will be printed on the bottom of HTG’s 96-well or 384-well plates.
Radany said the product will launch by the end of this year.
Competitors include companies like Randox, which sells cytokine arrays for use on its Evidence Investigator system; EMD Biosciences, which sells a 16-well multi-cytokine protein array; and Clontech, which has offered its Ab Array 500 for signal transduction, cell-cycle regulation, gene transcription, and apoptosis experiments, for nearly three years (see BAN 1/17/2006).
However, Radany said the firm’s primary competition will come from RT-PCR technology. Applied Biosystems currently offers TaqMan gene expression assays for cytokines, apoptosis, and cell cycle, while Panomics offers cytokine antibody and cytokine profiling assays.
HTG’s interest in selling content arrays has surfaced concurrently with administrative changes at the nine-year-old private company. Just last month Radany was named CEO of HTG, replacing Kirk Collamer, who has remained with HTG as its chief financial officer (see BAN 9/19/2006).
Radany said that the firm has continued to invest in its instrument and reagents business as well, and that customers can expect a new version of its Omix Imager that will be a benchtop model of its current system with slightly lower throughput. “The new imager will be lower cost for researchers” and will “target labs where throughput is not an issue,” Radany said.
Finally, he said that the company is also expanding the application capabilities for its flagship ArrayPlate system, which uses the company’s quantitative nuclease protection assay. According to Radany, while applications to date have been in gene expression, the firm is now selling ArrayPlate for use in miRNA profiling and proteomics.